GoKawiilOne spin-off just raised another $20 million. Colossal Biosciences claims to have brought back the dire wolf, and is now hard at work on its quest to resurrect several other species, including the woolly mammoth and the moa, a giant extinct bird. While that’s happening, the company is also pursuing a quieter, more near-term ambition: incubating a cadre of startups that can capitalize on Colossal’s technology and turn it into distinct businesses.
How Colossal is incubating an empire of startups
Why This Matters
Colossal Biosciences' efforts to revive extinct species highlight groundbreaking advancements in biotechnology, which could revolutionize conservation and genetic research. Simultaneously, its strategy to incubate startups leverages this innovation to create new market opportunities and drive industry growth. This dual approach underscores the transformative potential of biotech startups in shaping future technological and ecological landscapes.
Key Takeaways
- Colossal Biosciences is actively working on de-extinction projects like the woolly mammoth and dire wolf.
- The company is incubating startups to commercialize its biotech innovations.
- This approach could accelerate new industry developments and create significant economic impact in biotech and conservation.
Get alerts for these topics